A5085329460- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Cancer Diagnosis and Treatment
- Bone health and treatments
- PARP inhibition in cancer therapy
- Estrogen and related hormone effects
- Radiopharmaceutical Chemistry and Applications
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Treatments and Mutations
- Lymphoma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Melanoma and MAPK Pathways
- Chronic Lymphocytic Leukemia Research
- Cancer therapeutics and mechanisms
- BRCA gene mutations in cancer
- Chemotherapy-induced cardiotoxicity and mitigation
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
- PI3K/AKT/mTOR signaling in cancer
- Glycosylation and Glycoproteins Research
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
University of Rochester Medical Center
2020-2024
University of Alabama at Birmingham
2015-2024
Cancer Institute (WIA)
2023
University of Rochester
2020-2023
University of Alabama
2002-2020
Winship Cancer Institute
2017
Indiana University Health
2017
Georgetown University
2017
Methodist Hospital
2017
Aurora Health Care
2017
Abstract Background: Evaluation of the long-term benefit biologically-based regimens trastuzumab in early breast cancer population, and optimization integration to maximize efficacy minimize cardiac toxicity.Material Methods: We randomized HER2-positive (FISH+) patients with axillary lymph node positive or high risk negative, either standard AC (60/600 mg/m2 q3wk x4) followed by T (100 x 4) two trastuzumab-containing regimens; 1 year TCarbo (75 mg/m2/AUC6 6) year. Patients were prospectively...
Abstract The production of exosomes by tumor cells has been implicated in tumor-associated immune suppression. In this study, we show that, mice, produced TS/A murine mammary target CD11b+ myeloid precursors the bone marrow (BM) vivo, and that is associated with an accumulation spleen. Moreover, demonstrate block differentiation precursor into dendritic (DC) vitro. Addition at day 0 led to a significant DC, whereas addition later time points was less effective. Similarly, human breast...
This randomized, multicenter, phase III study compared doxorubicin and docetaxel (AT) with cyclophosphamide (AC) as first-line chemotherapy (CT) in metastatic breast cancer (MBC).Patients (n = 429) were randomly assigned to receive 50 mg/m(2) plus 75 214) or 60 600 215) on day 1, every 3 weeks for up eight cycles.Time progression (TTP; primary end point) time treatment failure (TTF) significantly longer AT than AC (median TTP, 37.3 v 31.9 weeks; log-rank P =.014; median TTF, 25.6 23.7...
A significant proportion of patients with early-stage triple-negative breast cancer (TNBC) are treated neoadjuvant chemotherapy. Sequencing circulating tumor DNA (ctDNA) after surgery, along enumeration cells (CTCs), may be used to detect minimal residual disease and assess which experience recurrence.To determine whether the presence ctDNA CTCs chemotherapy in TNBC is independently associated recurrence clinical outcomes.A preplanned secondary analysis was conducted from March 26, 2014,...
PURPOSE To investigate the response rate, time to treatment failure (TTF), overall survival, and toxicity in patients with metastatic melanoma treated dacarbazine alone, plus interferon (IFN), tamoxifen (TMX), or IFN TMX. MATERIALS AND METHODS Two hundred seventy-one (258 were eligible) randomized a 2 x factorial design receive one of above treatments. The trial was designed detect 50% improvement survival 83% power. RESULTS Nine complete (CRs) 18 partial responses (PRs) observed who...
Sixty-four patients with histologically confirmed metastatic malignant melanoma were entered on a prospectively controlled randomized trial. Patients received dacarbazine (DTIC) alone or DTIC plus interferon (IFN) alfa-2b. reasonably balanced respect to age, sex, performance status (PS), site of metastases, and number sites. Objective response (complete partial remission [CR + PR]) was documented in six 16 IFN Median time treatment failure (TTF) median survival are significantly better the...
<h3>Importance</h3> Treatment options for patients with disease progression after treatment trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1) are limited. Tucatinib is an oral, potent, human epidermal growth factor receptor 2 (HER2)-specific tyrosine kinase inhibitor (TKI) being developed as a novel for<i>ERBB2/HER2</i>-positive breast cancer. <h3>Objective</h3> To determine the maximum tolerated dosage of tucatinib in combination T-DM1 with<i>ERBB2/HER2</i>-positive metastatic...
Abstract Purpose: The mechanisms by which trastuzumab imparts clinical benefit remain incompletely understood. Antibody-dependent cellular cytotoxicity via interactions with Fcγ receptors (FcγR) on leukocytes may contribute to its antitumor effects. Single-nucleotide polymorphisms (SNP) in FCGR3A and FCGR2A genes lead amino acid substitutions at positions 158 131, respectively, affect binding of antibodies FcγR such that 158V/V 131H/H bind highest affinity. This study aimed determine whether...
PURPOSE: The identification of a subset patients with axillary lymph node–positive breast cancer an improved prognosis would be clinically useful. We report the prognostic importance histologic grading and proliferative activity in cohort compare these parameters other established factors. PATIENTS AND METHODS: This Eastern Cooperative Oncology Group laboratory companion study (E4189) centered on 560 registered onto one six eligible clinical protocols. Flow cytometric (ploidy S-phase...
Abstract Background Adjuvant bisphosphonates, when given in a low-estrogen environment, can decrease breast cancer recurrence and death. Treatment guidelines include recommendations for adjuvant bisphosphonates postmenopausal patients. SWOG/Alliance/Canadian Cancer Trials Group/ECOG-ACRIN/NRG Oncology study S0307 compared the efficacy of three early-stage cancer. Methods Patients with stage I–III were randomly assigned to 3 years intravenous zoledronic acid, oral clodronate, or ibandronate....
LBA501 Background: I-SPY2.2 is a multicenter phase 2 platform sequential multiple assignment randomized trial (SMART) in the neoadjuvant breast cancer setting that evaluates novel experimental regimens as first sequence (Block A) followed by standard chemo/targeted therapies (Blocks B/C) if indicated. The goal to achieve pCR after targeted agents alone or with therapies, optimal therapy assigned based on tumor response predictive subtype (RPS). RPS incorporates expression-based immune, DNA...
PURPOSE: Several groups have reported that the combination of doxorubicin plus paclitaxel given as a 3-hour intravenous (IV) infusion for up to eight cycles produces high response rate (> 80%) and complete 20%) in metastatic breast cancer, but is also complicated by 20% incidence congestive heart failure (CHF). The purpose this phase II trial was evaluate antineoplastic activity regimen multi-institutional setting reduce cardiotoxicity limiting treatment maximum six cycles. PATIENTS AND...
Lapatinib plus trastuzumab improves outcomes relative to lapatinib alone in heavily pretreated, human epidermal growth factor receptor 2-positive metastatic breast cancer (MBC). We tested the combination earlier-line setting and explored predictive value of [(18)F]fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) for clinical outcomes.Two cohorts were enrolled (cohort 1: no prior MBC ≥ 1 year from adjuvant trastuzumab, if given; cohort 2: one two lines chemotherapy including...
Cotargeting the mammalian target of rapamycin pathway and estrogen receptor may prevent or delay endocrine resistance in patients receiving first-line treatment for advanced breast cancer.To investigate combination everolimus plus therapy second-line settings postmenopausal women with receptor-positive, human epidermal growth 2-negative cancer.In multicenter, open-label, single-arm, phase 2 BOLERO-4 (Breast Cancer Trials Oral Everolimus) clinical trial, 245 were screened eligibility; 202...
Patients with triple-negative breast cancer (TNBC) residual disease after neoadjuvant chemotherapy (NAC) have high risk of recurrence prior data suggesting improved outcomes capecitabine. Targeted agents demonstrated activity across multiple types. BRE12-158 was a phase II, multicenter trial that randomly allocated patients TNBC NAC to genomically directed therapy versus treatment physician choice (TPC).From March 2014 December 2018, 193 were enrolled. Residual tumors sequenced using...
Squamous cell cancer of the esophagus is most common among black South African males, and 60% patients present with localized inoperable disease. Combined chemoradiotherapy has been reported to be superior radiotherapy alone for esophageal in North American patients. A study was carried out determine if this also applicable patients, who more advanced From September 1991 through June 1995, 70 locally (T3N0-1M0) squamous were prospectively randomized receive or combined cisplatin...
Six hundred twenty-four women with metastatic breast cancer were entered on Eastern Cooperative Oncology Group (ECOG) study EST 2181. Patients treated mitolactol, doxorubicin, vincristine (DAV), tamoxifen, and fluoxymesterone (DAVTH). Nine patients canceled, 114 ineligible (half because of concomitant diseases). Among the 501 eligible patients, overall response rate was 54% (14% complete 5% not assessable). The median time to treatment failure (TTF) 9.0 months, survival 20.9 months....
Abstract Background Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1/2 (g ) mutations, and efforts to expand the utility of PARPi beyond are ongoing. In preclinical models triple-negative breast (TNBC) intact DNA repair, we previously shown an induced synthetic lethality combined EGFR inhibition PARPi. Here, report safety clinical activity lapatinib veliparib in metastatic TNBC. Methods A first-in-human, pilot study was conducted TNBC...
Abstract Purpose: Pelareorep (Pel) is a type 3 oncolytic reovirus that upregulates PD-L1 expression. We determined the objective response rate (ORR) with paclitaxel (Pac), Pac + Pel, or Pel avelumab (Ave). Patients and Methods: hormone receptor positive (HR+) HER2 negative metastatic breast cancer (MBC) who had progressed on at least one line of endocrine therapy CDK 4/6 inhibitor not received chemotherapy for MBC were eligible. randomized 1:1:1 to Pac, Pac/Pel Pac/Pel/Ave after...